These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19355935)

  • 1. AD vaccines: conclusions and future directions.
    Wisniewski T
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):160-6. PubMed ID: 19355935
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.
    Wisniewski T; Boutajangout A
    Brain Struct Funct; 2010 Mar; 214(2-3):201-18. PubMed ID: 20012091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative Abeta immunotherapy approaches for Alzheimer's disease.
    Town T
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):114-27. PubMed ID: 19355932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial.
    Kokjohn TA; Roher AE
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):88-97. PubMed ID: 19355930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid-beta immunotherapy for Alzheimer's disease.
    Fu HJ; Liu B; Frost JL; Lemere CA
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-beta immunisation for Alzheimer's disease.
    Wisniewski T; Konietzko U
    Lancet Neurol; 2008 Sep; 7(9):805-11. PubMed ID: 18667360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active and passive Abeta-immunotherapy: preclinical and clinical studies and future directions: part II.
    Cribbs DH; Agadjanyan MG
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):82-7. PubMed ID: 19355929
    [No Abstract]   [Full Text] [Related]  

  • 8. Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.
    Ghochikyan A
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):128-43. PubMed ID: 19355933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention.
    Tarawneh R; Holtzman DM
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):144-59. PubMed ID: 19355934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in a natural model of Abeta pathogenesis: the aging beagle.
    Vasilevko V; Head E
    CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):98-113. PubMed ID: 19355931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's disease: Mental plaque removal.
    De Strooper B; Woodgett J
    Nature; 2003 May; 423(6938):392-3. PubMed ID: 12761533
    [No Abstract]   [Full Text] [Related]  

  • 12. Setback for an Alzheimer's disease vaccine: lessons learned.
    Mathews PM; Nixon RA
    Neurology; 2003 Jul; 61(1):7-8. PubMed ID: 12847147
    [No Abstract]   [Full Text] [Related]  

  • 13. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.
    Petrushina I; Ghochikyan A; Mktrichyan M; Mamikonyan G; Movsesyan N; Davtyan H; Patel A; Head E; Cribbs DH; Agadjanyan MG
    J Neurosci; 2007 Nov; 27(46):12721-31. PubMed ID: 18003852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active Immunotherapy to Prevent Alzheimer Disease-A DNA Amyloid β 1-42 Trimer Vaccine.
    Rosenberg RN; Lambracht-Washington D
    JAMA Neurol; 2020 Mar; 77(3):289-290. PubMed ID: 31816028
    [No Abstract]   [Full Text] [Related]  

  • 15. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.
    Long JM; Holtzman DM
    Cell; 2019 Oct; 179(2):312-339. PubMed ID: 31564456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. APP transgenic mouse models and their use in drug discovery to evaluate amyloid- lowering therapeutics.
    Hussain I
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):395-402. PubMed ID: 20522015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatments for Alzheimer's disease emerge.
    Selkoe DJ
    Science; 2021 Aug; 373(6555):624-626. PubMed ID: 34353940
    [No Abstract]   [Full Text] [Related]  

  • 18. Will anti-amyloid therapies work for Alzheimer's disease?
    St George-Hyslop PH; Morris JC
    Lancet; 2008 Jul; 372(9634):180-2. PubMed ID: 18640437
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease.
    Kou J; Song M; Pattanayak A; Lim JE; Yang J; Cao D; Li L; Fukuchi K
    J Neuroimmunol; 2012 Mar; 244(1-2):70-83. PubMed ID: 22326143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
    Menéndez-González M; Pérez-Piñera P; Martínez-Rivera M; Muñiz AL; Vega JA
    Curr Pharm Des; 2011; 17(5):508-20. PubMed ID: 21375481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.